.jpg "How to Claim Your Cut of Apple’s 0 Million Siri Settlement")
The Global Burden of Type 1 Diabetes Is Not Shared Equally
People with this autoimmune disease face much shorter life expectancies in lower-income nations.
This video is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex.
Carin Leong: Type 1 diabetes is rising around the world—and no one knows why.
On supporting science journalism
If you’re enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
So type 1 diabetes—unlike type 2—is an autoimmune disease. It happens when your immune system attacks the pancreas cells that make insulin. No insulin means your blood sugar skyrockets, and without treatment, it can be deadly.
Scientists aren’t totally sure why cases are climbing. It’s partly because we’ve gotten better at detecting type 1 diabetes early on. But that’s not the whole story. Researchers have a handful of hypotheses—like maternal and early-childhood diets, exposure to microbes in the environment, viral infections early in life or even gut bacteria—that could be potential factors in triggering this autoimmune condition.
Treatment of type 1 diabetes has come a long way, but the advancements aren’t shared equally. In rich countries, a 10-year-old diagnosed with type 1 diabetes has access treatments. This can be insulin therapy, glucose monitors or even artificial pancreas technology. And they can live well into their 70s, which is not far from the life expectancy of the general population. In poorer countries, that same 10-year-old child might live just 10 more years.
Experts say millions of lives can be saved if early diagnosis and treatment are available worldwide. Type 1 diabetes isn’t a death sentence, but where you live can make it one.
It’s Time to Stand Up for Science
If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.
I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.
If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.
In return, you get essential news, captivating podcasts, brilliant infographics, can’t-miss newsletters, must-watch videos, challenging games, and the science world’s best writing and reporting. You can even gift someone a subscription.
There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.
